DELVING DEEPER INTO CLINICAL DEVELOPMENT CONSIDERATIONS FOR NOVEL FOOD ALLERGY THERAPEUTICS

Time: 9:10 am
day: Day Two

Details:

Many companies are trying to start the first in-human studies considering the FDA’s recent approval of the first medicine to treat peanut allergies. To set up for long-term success, it is crucial to comprehend the translational route, from a complete grasp of the regulatory mechanisms to finding the appropriate dose to translate into people. These translational difficulties will be addressed in this section to guarantee a strong, thorough approach to entering the clinic.